• Schriftgröße:
  • Schriftgröße 1
  • Schriftgröße 2
  • Schriftgröße 3
  • Schriftgröße 4
  • Schriftgröße 5
Prof. Dr. C. Hamm

prof. hamm 11 web

Prof. Dr. med. Christian Hamm

Implantation eines Mitraclips

Implantation eines Mitraclips

Wissenschaftliche Originalarbeiten

Bisher sind seit 1980 215 wissenschaftliche Originalarbeiten veröffentlicht worden.

Veröffentlichungen seit 2003:

  1. Heeschen C, Dimmeler St, Hamm CW, Boersma E, Zeiher AM, Simoons ML, on behalf of the CAPTURE Investigators: Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation 107: 524-530, 2003
  2. Heeschen C, Dimmeler St, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML for the CAPTURE Study Investigators: Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348; 1104-1111, 2003
  3. Dill T, Neumann T, Ekinci O, Breidenbach C, John A, Erdogan A, Bachmann G, Hamm CW, Pitschner HF: Pulmonary vein diameter reduction after radiofrequency catheter ablation for paroxysmal atrial fibrillation evaluated by contrast-enhanced three-dimensional magnetic resonance imaging. Circulation 107; 845-850, 2003
  4. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, Zeiher AM for the CAPTURE Study Investigators: Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 107: 2109-2114, 2003
  5. Lenderink T, Boersma E, Heeschen C, Vahanian A, de Boer MJ, Umans V, van den Brand MJBM, Hamm CW, Simoons ML, for the CAPTURE investigators: Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA. Eur Heart J 24: 77-85, 2003
  6. John AS, Dill T, Brandt RR, Rau M, Ricken W, Bachmann G, Hamm CW: Magnetic resonance to assess the aortic valve area in aortic stenosis. JACC 42: 519-526, 2003
  7. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, Simoons ML, Hamm CW, on behalf of the CAPTURE Investigators: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108:1440-1445, 2003
  8. CW Hamm, Hugenholtz PG, for the TRUST Investigators: Silicon carbide-coated stents in patients with acute coronary syndrome. Catheter Cardiovasc Interv 60: 375-381, 2003
  9. Schächinger V, Hamm CW, Münzel T, Haude M, Baldus S, Grube E, Bonzel T, Konorza T, Köster R, Arnold R, Haase J, Probst P, vom Dahl J, Neumann FJ, Mudra H, Hennen B, Thiele L, Zeiher AM, and STING (STents IN Grafts) Investigators: A randomized trial of polytetrafluorethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts. JACC 42 (8): 1360-1362, 2003
  10. Hamm CW, Schächinger V, Münzel Th, Maikowski C, Bonzel T, Köster R, Rau M, Zeiher A: Peptide-treated stent graft for the treatment of saphenous vein graft lesions: first clinical results. J Invas Cardiol: 15: 557-560, 2003
  11. Heeschen C, Dimmeler S, Fichtlscherer S, Hamm CW, Berger J, Simoons ML, Zeiher AM, for the CAPTURE Investigators: Prognostic value of placental growth factor in patients with acute chest pain. JAMA 291: 435-441, 2004
  12. Zahn R, Hamm CW, Zeymer U, Schneider S, Nienaber CA, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Schöbel WA, Sabin G, Senges J, für das deutsche CypherTM-Register: Aktuelle Indikationsstellung und Sicherheit beim Einsatz des koronaren Sirolimus-Stents im klinischen Alltag in Deutschland. Herz 29: 181-186, 2004
  13. Weber M, Neumann T, Rau M, Brandt R, Dill T, Maikowski C, Mitrovic V, Hamm C: Verbesserung der kardiopulmonalen Belastbarkeit nach interventionellem ASD-Verschluss. Z Kardiol 93: 209-215, 2004
  14. Zahn R, Hamm CW, Zeymer U, Schneider S, Nienaber CA, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Schöbel WA, Sabin G, Senges J, for the German CypherTM Registry: „Real life“ use of sirolimus-eluting coronary stents in Germany. Z Kardiol 93: 287-294, 2004
  15. Dietz U, Baldus S, Rupprecht HJ, Küchler R, vom Dahl J, Ekinci O, Hamm C: Angiographic outcome in multivessel disease (GABI II study) using neu coronary device interventions and comparison with GABI I trial results. Cardiology 102: 24-31, 2004
  16. Elsässer A, Vogt AM, Nef H, Kostin S, Möllmann H, Skwara W, Bode C, Hamm C, Schaper J: Human hibernating myocardium is jeopardized by apoptotic and autophagic cell death. JACC 43: 2191-2199, 2004
  17. Zahn R, Hamm CW, Zeymer U, Schneider S, Nienaber CA, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G, Senges J, pour le registre allemand sur Cypher: Stent Cypher: le Registre allemand. Résultats du registre prospectif multicentrique allemand sur Cypher. Annales de Cardiologie et d'Angéiologie 53: 36s-39s, 2004
  18. Dill T, Breidenbach C, John A, Brandt RR, Ekinci O, Szalay Z, Bauer EP, Ricken W, Bachmann G, Hamm CW: Pre- and postoperative assessment of left ventricular function by magnetic resonance imaging and 2-D-echocardiography in patients undergoing left ventricular aneurysmectomy. Thorac Cardiov Surg 52: 274-279, 2004
  19. Heeschen C, Hamm CW, Mitrovic V, Nicte-Ha L, White HD, for the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators: N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Ciruclation 110: 3206-3212, 2004
  20. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML, Zeiher AM, for the CAPTURE Study Investigators: Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes. J Am Coll Cardiol 45: 229-237, 2005
  21. Khattab AA, Levenson B, Hamm CW et al.: Sirolimus-eluting stent treatment for isolated proximal left anterior descending artery stenoses. Z Kardiol 94: 187-192, 2005
  22. Mitrovic V, Klein HH, Krekel N, Kreuzer J, Fichtlscherer S, Schirmer A, Paar WD, Hamm CW: Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis. Z Kardiol 94: 336-342, 2005
  23. Weber M, Arnold R, Rau Matthias, Elsaesser A, Brandt R, Mitrovic V, Hamm C: Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J 26: 1023-1030, 2005
  24. Zahn R, Hamm CW, Schneider S, Zeymer U et al.: Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the Prospective Multicenter German Cypher Stent Registry). Am J Cardiol 95: 1302-1308, 2005
  25. Wijns W, Verheye S, Monoharan G, Werner GS, Grube E, De Bruyne B, Koolen J, Hamm CW et al, for the CONVERTIBLE investigators: Angiographc, intravascular ultrasound, and fractional flow reserve evaluation of direct stenting vs. conventional stenting using BeStent2 in a multicentre randomized trial. Eur Heart J 26: 1852-1859, 2005
  26. Serruys PW, Ong ATL, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Otto-Terlouw PC: A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention 1: 58-65, 2005
  27. Elsässer A, Möllmann H, Nef H, Dill T, Brandt R, Skwara W, Hennig T, Rau M, Hamm C: Transcatheter closure of a ruptured ventricular septum after myocardial infarction using a venous approach. Z Kardiol 94: 684-689, 2005
  28. Tsuchida K, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher AM, Grube E, Haase J, Thuesen L, Hamm CW, Veldhof S, Dorange C, Serruys PW: One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST trial). EuroIntervention 1 (nr 3): 266-272, 2005
  29. Deetjen A, Möllmann S, Dill T, Hamm CW: Left atrial myxoma diagnosed and characterized by cardiac magnetic resonance imaging. Z Kardiol 94: 695-698, 2005
  30. Brandt RR, Arnold R, Bohle RM, Dill T, Hamm CW: Cardiac angiosarcoma: case report and review of the literature. Z Kardiol 94: 824-828, 2005
  31. Rau M, Maikowski C, Weber M, Keil E, Elsässer A, Möllmann H, Hamm C: Treatment of in-stent restenosis with sirolimus-eluting-stents – A six month clinical and angiographic follow-up. Z Kardiol 94: 742-747, 2005
  32. Brandt RR, Reiner C, Arnold R, Sperzel J, Pitschner HF, Hamm CW: Contractile response and mitral regurgitation after temporary interruption of long-term cardiac resynchronization therapy. Eur Heart J 27: 187-192, 2006
  33. Lenderink T, Heeschen C, Fichtlscherer S, Dimmeler S, Hamm CW, Zeiher AM, Simoons ML, Boersma E, and CAPTURE Investigators: Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. JACC 47 (No.2): 307-311, 2006
  34. Burian M, Neumann T, Weber M, Brandt R, Geisslinger G, Mitrovic V, Hamm C: Nickel release, a possible indicator for the duration of antiplatelet treatment, from a nickel cardiac device in vivo: a study in pateints with atrial septal defects implanted with an Amplatzer occluder. International Journal of Clinical Pharmacology and Therapeutics: 44 (No. 3): 107-112, 2006
  35. Bhatt DL, Fox KAA, Hacke ChB, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW et al., for the CHARISMA Investigators: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events: N Engl J Med 354: 1706-1717, 2006
  36. Lenderink T, Heeschen C, Fichtlscherer S, Dimmeler S, Hamm CW, Zeiher AM, Simoons ML, Boersma E, for the CAPTURE Investigators: Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. JACC 47: 307-311, 2006
  37. Weber M., Kleine C, Keil E, Rau M, Berkowitsch A, Elsaesser A., Mitrovic V, Hamm C: Release pattern of N-terminal pro B-typenatriuretic peptide (NT-proBNP) in acute coronary syndromes. Clin Res Cardiol 95: 270-280, 2006
  38. Zahn R, Hamm CW, Schneider S, Zeymer U, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G, Nienaber CA, Senges J, for the German Cypher Stent Registry: Predictors of death or myocardial infarction during follow-up after coronary stenting with the Sirolimus-eluting stent. Am Heart J 152: 1146-1152, 2006.
  39. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey D, Hamm C, Süselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM, fort he REPAIR-AMI investigators: Intracoronary bone marrow-derived progenitor cells in patients with acute myocardial infarction. N Engl J 355: 1210-1221, 2006.
  40. Möllmann H, Nef HM, Kostin S, von Kalle C, Pilz I, Weber M, Schaper J, Hamm CW, Elsässer A: Bone marrow-derived cells contribute to infarct remodelling. Cardiovascular Research 71: 661-671, 2006
  41. Deetjen A, Conradi G, Möllmann S, Kluge A, Hamm CW, Dill T: Cardiac metastasis of a renal cell adenocarcinoma investigated by cardiac magnetic resonance imaging. Clin Res Cardiol 95: 492-495, 2006
  42. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW et al. for the REPAIR-AMI Investigators: Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year result of the REPAIR-AMI trial. Eur Heart J 27: 2775-2783, 2006
  43. Zahn et al. Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry. Am Heart J 152(6): 1146-52, 2006
  44. Conradi G, Deetjen A, Möllmann S, Hamm CW, Dill T: Symptomatic atrial fibrillation as the first symptom of a ginat left atrial appendage aneurysm. Clinical Research in Cardiology 95: 614-616, 2006
  45. Weber M, Hausen M, Arnold R, Nef H, Moellmann H, Berkowitsch A, Elsaesser A, Brandt R, Mitrovic V, Hamm C: Prognostic values of N-terminal pro-B-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis. Heart 92: 1639-1644, 2006
  46. Neumann T, Erdogan A, Dill T, Greiss H, Berkowitsch A, Sperzel J, Kuniss M, Kurzidim K, Hamm CW, Pitschner HF: Asymptomatiac recurrences of atrial fibrillation after pulmonary vein isolation. Europace 8 (7): 495-498, 2006
  47. Zahn R, Nienaber CA, Hamm CW, Weber F et al., for the German Cypher Stent Registry: The sirolomus-eluting coronary stent in clinical practice: impact of direct stenting versus stenting with balloon pre-dilatation. EuroIntervention (Vol 2, NB.4) 459-466, Feb. 2007
  48. Tsuchida K, Colombo A, Lefèvre T, Oldroyd KG, Guetta V, Guagliumi G, von Scheidt W, Ruzyllo W, Hamm CW et al.: The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularization Therapies Study part II (ARTS II). Eur Heart J 28 (no. 4): 433-442, 2007
  49. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW et al., for the CHARISMA Investigators: Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. JACC 49 (no. 19): 1982-1988, 2007
  50. Khattab AA, Levenson B, Hamm CW et al., for the German Cypher Stent Registry: Incidence and predictors of target vessel revascularization after sirolimus-eluting stent treatment for proximal left anterior descending artery stenoses among 2274 patients from the prospective multicenter German Cypher Stent Registry. Clin Res Cardiol 96: 279-284, 2007
  51. Zahn R, Hamm CW, Schneider S, et al., fort he German Cypher Stent Registry: The Sirolimus-eluting coronary stent in daily routine practice in Germany: Trends in indications over the years. Clin Res Cardiol 96: 548-556, 2007
  52. Khattab AA, Hamm CW, Senges J et al., for the German Cypher Registry: Sirolimus-eluting stent treatment for unprotected versus protected left main coronary artery disease in widespread clinical routine: 6-month and 3-year clinical follow-up results from the prospective multicentre German Cypher Registry. Heart 93: 1251-1255, 2007
  53. Brüggenjürgen B, McBride D, Bode C, Hamm CW, Kuck KH, Willich SN: Sirolimus-eluting versus bare-metal stents for the reduction of coronary restenosis. Herz 32 (Nr. 8): 650-655, 2007
  54. Möllmann H, Zirlik A, Nef HM, Weber M, Hamm CW, Elsässer A: Left ventricular tamponade – a clinical chameleon. Thorac Cardiovasc Surg 55 (5): 325-327, 2007
  55. Nef H, Möllmann H, Kostin S, Troidl C, Voss S, Weber M, Dill T, Rolf A, Brandt R, Hamm CW, Elsässer A: Tako-Tsubo cardiomyopathy: intraindividual structural analysis in the acute phase and after functional recovery. Eur Heart J 28 (/30): 2456-2464, 2007
  56. Deetjen A, Möllmann S, Conradi G, Rolfa A, Schmermund A, Hamm CW, Dill T: Use of automatic exposure control in multislice computed tomography of the coronaries: comparison of 16-slice and 64-slice scanner data with conventional coronary angiography. Heart 93(9): 1040-1043, 2007
  57. Weber M, Rabenau B, Stanisch M, Nef HM, Möllmann H, Elsässer A, Mitrovic V, Heeschen C, Hamm C: Influence of sample type on soluble CD40 ligand assessment in patients with acute coronary syndromes. Thromb Res 120 (6): 811-814, 2007
  58. Nef H, Möllmann H, Troidl C, Kostin S, Böttger T, Voss S, Hilpert P, Krause N, Weber M, Rolfa A, Dill T, Schaper J, Hamm CW, Elsässer A: Expression profiling of cardiac genes in Tako-Tsubo cardiomyopathy: insight into a new cardiac entity. Journal of Molecular and Cellular Cardiology 44 (No. 2): 395-404, 2008
  59. Nef HM, Möllmann H, Hilpert P, Masseli F, Kostin S, Troidl C, Rolf A, Dill T, Weber M, Hamm C, Elsässer A: Sympathoadrenergic overstimulation in Tako-Tsubo cardiomyopathy triggered by physical and emotional stress. Int J Carddiol 130 (No. 2): 266-268, 2008
  60. Dill T, Deetjen A, Ekinci O, Möllmann S, Conrade G, Kluge A, Weber C, Weber M, Nef H, Hamm CW: Radiation dose exposure in multislice computed tomography of the coronaries in comparison with conventional coronary angiography. Int J Cardiol 124 (No. 3): 307-311, 2008
  61. Weber M, Bazzino O, Estrada JN, Fuselli JJ, Botto F, Perez de Arenaza D, Möllmann H, Nef HN, Elsässer A, Hamm CW: N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission. JACC 51 (no. 12): 1188-1195, 2008
  62. Weber FD, Schneider H, Wiemer M, Pfannebecker T, Tebbe U, Hamm CW, Senges J, Schneider S, Nienaber CA: Sirolimus eluting stent (CypherTM) in patients with diabetes mellitus: results from the German Cypher Stent Registry. Clin Res Cardiol 97: 105-109, 2008
  63. Serruys P W, Daemen J, Morice M-C, De Bruyne B, Colombo A, Macaya Carlos, Richardt G, Fajadet J, Hamm C et all.; on behalf of the ARTS-II Investigators: Three-year follow-up of the ARTS-II-sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. EuroIntervention (3): 450-459, 2008
  64. Neumann T, Vogt J, Schumacher B, Dorszewski A, Koller M, Heintze J, Scholz U, Wetzel U, Schneider MAE, Horstkotte D, Hamm C, Pitschner HF; Circumferential Pulmonary Vein Isolation With the Cryoballoon Technique. JACC (4): 273-278, 2008
  65. Möllmann H, Elsässer A, Nef H, Schneider S, Nienaber C, Richardt G, Weber M, Kelm M, Lebenson B, Bonzel T, Tebbe U, Sabin G, Pfannebecker T, Senges J, Hamm CW: Treatment of in-stent restenosis with sirolimus-eluting-stents: results from the prospective German Cypher stent registry. Clin Res Cardiol 97: 432-440, 2008
  66. Serruys PW, Garcia-Garcia HM, Buszman P, … Hamm CW, for the Integrated Biomarker and Imaging Study-2 Investigators: Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118: 1172-1182, 2008
  67. van't Hof AWJ, ten Berg J, Heestermans T, … Hamm C, on behalf of the Ongoing Tirofiban in Myocardial infarction Evaluation (on-TIME) 2 study group: Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME2): a multicentre, double-blind, randomised controlled trial. The Lancet 372 (August 16): 537-546, 2008
  68. Neumann T, Vogt J, Schumacher B, … Hamm CW: Circumferential pulmonary vein isolation with the cryoballoon technique. JACC 52 (No. 4): 273-278, 2008
  69. Eikelboom JW, Hankey GJ, Thom J, … Hamm C, on behalft of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators: Circulation 118 (no. 17): 1705-1712, 2008
  70. Erkapic D, Rixe J, Struönk J, Hamm CW, Dill T: Acute aortitis with spinal artery aneurysms detected by contrast enhance magnetic resonance imaging. Clin Res Cardiol 98: 59-61, 2009
  71. Vaina S, Voudris V, Morice MC, de Bruyne B, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, Schuijer M, Marcours N, Stoll H-P, Cokkinos D, Stefanadis C, Serruys PW, on behalf of the ARTSII investigators: Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularisation in patients with multivessel coronary artery disease: Insights from ARTS I and ARTS II. EuroInterv 4: 492-501, 2009
  72. Mak H-H, Bhatt DL, Shao M, Haffner SM, Hamm CW, Hankey GJ, Claiborne Johnston S, Montalescot G, Steg PG, Steinhubl SR, Fox KAA, Topol EJ: The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur Heart J 30: 857-865, 2009
  73. Mitrovic V, Appel KF, Proskynitopoulos N, Dereli S, Hamm CW: Effects of candesartan cilexetil "add-on" treatment in congestive heart failure outpatients in daily practice. Clin Res Cardiol 98 (no. 6): 379-389, 2009
  74. Htlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrié D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb WA, Kähler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ: Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. The Lancet 373: 1190-1197, 2009
  75. Routledge HC, Lefèvre T, Colombo A, Oldroyd KG, Hamm CW, Guagliumi G, von Scheidt W, Guetta V, Ruzyllo W, Wittebols K, Goedhart D, Serruys PW: Three-year clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularisation Therapies Study, part II (ARTS II). EuroIntervention: 5 (no 2): 190-196, 2009
  76. Nef HM, Möllmann H, Hilpert P, Troidl C, Voss S, Rolf A, Behrens CB, Weber M, Hamm CW, Elsässer A: Activated cell survival cascade protects cardiomyocytes from cell death in Tako-Tsubo cardiomyopathy. Eur J Heart Failure 11: 758-765, 2009
  77. Nef HM, Möllmann H, Jospeh A, Troidl C, Voss S, Rauch M, Kinscherf R, Vogt A, Weber M, Hamm CW, Elsässer A: Reduction of neointimal hyperplasis in porcine coronary arteries by 2-deoxy-D-glucose. Clin Res Cardiol 98: 355-361, 2009
  78. Mitrovic V, Appel KF, Proskynitopoulos N, Dereli S, Hamm CW: Effects of Candesartan cilexetil "add-on" treatment in congestive heart failure outpatients in daily practice. Clin Res Cardiol 98: 379-389, 2009
  79. Nef HM, Möllmann H, Troidl C, Kostin S, Voss S, Hilpert P, Behrens CB, Rolf A, Rixe J, Weber M, Hamm CW, Elsässer A: Abnormalities in intracellular Ca²+ regulation contribute to the pathomechanism of Tako-Tsubo cardiomyopathy. Eur Heart J 30 (no. 17): 2155-2164, 2009
  80. Rolf A, Nef HM, Möllmann H, Troidl C, Voss S, Conradi G, Rixe J, Steiger H, Beiring K, Hamm CW, Dill T: Immunohistological basis of the late gadolinium enhancement phenomenon in tako-tsubo cardiomyopathy. Eur Heart J 30: 1635-1642, 2009
  81. Schächinger V, Assmus B, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Yu J, Corti R, Mathey DG, Hamm CW, Tonn T, Dimmeler S, Zeiher M, for the REPAIR-AMI investigators: Intracoronary infusion of bonw marrow-derived mononuclear cells abrogates adverse left ventricular remodelling post-acute myocardial infarction: insights from the reinfusion of enriched progenitor cells and infarct remodelling in acute myocardial infarction (REPAIR-AMI) trial. European Journal of Heart Failure 11: 973-979, 2009
  82. Nef HM, Möllmann H, Weber M, Auch-Schwelk W, Bonzel T, Varelas J, Nordt TK, Schofer J, HH Minden, Stumpf J, Schneider S, Elsässer A, Hamm CW: Cobalt-chrome MULTI-LINK VISION™-stent implantation in diabetics and complex lesions: results from the DaVinci-Registry. Clin Res Cardiol 98 (no. 11): 731-737, 2009
  83. Krause K, Adamu U, Weber M, Hertting K, Hamm C, Kuck KH, Hoffmann R, Kelm M, Blindt R: German stereotaxis-guided percutaneous coronary intervention study group: first multicenter real world experience. Clin Res Cardiol 98 (no. 9): 541-547, 2009
  84. Kukreja N, Serruys PW, De Bruyne B, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, Goedhart D, Macours N, Stoll HP for the ARTS-II Investigators: Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II). Heaert 95 (no. 13): 1061-1066, 2009
  85. Khattab AA, Hamm CW, Senges J, Toelg R, Geist V, Bonzel T, Kelm M, Levenson B, Nienaber CA, Pfannebecker T, Sabin G, Schneider S, Tebbe U, Neumann FJ, Richardt G, for the German Cypher Registryet al: Sirolimus-eluting stent treatment at high-volume centers confers lower mortality at 6-month follow-up. Results from the Prospective Multicenter German Cypher Registry. Circulation 120: 600-606, 2009
  86. Zahn R, Hamm CW, Zeymer U, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G, Nienaber CA, Pfannebecker T, Senges J: Coronary stenting with the sirolimus-eluting stent in patients with restenosis after intracoronary brachytherapy: results from the prospective multicentre German Cypher Stent Registry. Clin Res Cardiol 99: 99-106, 2010
  87. Zahn R, Hamm CW, Schneider S, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G, Nienaber CA, for the German Cypher Stent Registry: Coronary stenting with the sirolimus-eluting stent in clinical practice: Final results from the Prospective Multicenter German Cypher Stent Registry. J Interv Cardiol 23: 18-25, 2010
  88. Valgimigly M, Biondi-Zoccai G, Tebaldi M, van’t Hof AWJ, Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, Moliterno DJ, Topol EJ: Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J: 31: 35-49, 2010
  89. Assmus B, Rolf A, Erbs, S, Elsässer A, Haberbosch W, Hambrecht R, tillmanns H, Jiangtao Yu, Corti R, Mathey DG, Hamm CW, Süselbeck T, Tonn T, Dimmeler S, Dill T, Zeiher AM, Schächinger V, for the REPAIR-AMI Investigators: Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail 3: 89-96, 2010
  90. Zahn R, Hamm CW, Zeyer U, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G, Nienaber CA, Pfannebecker T, Senges J: Coronary stenting with the sirolimus-eluting stent in patients with restenosis after intracoronary brachytherapy: results from the prospective multicentr German Cypher Stent Registry. Clin Res Cardiol 99: 99-106, 2010
  91. van Domburg RT, Daemen J, Morice MC, de Bruyne B, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, van Es GA, Wittebols K, Macours N, Stoll HP, Serruys PW, on behalf of the ARTS-II Investigators: Short- and long-term health related quality-of-life and angina status of the Arterial Revascularisation Therapies Study part II, ARTS-II; sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease.EuroIntervention 5: 962-967, 2010
  92. Welsh RC, Granger CB, Westerhout CM, Blankenship JC, Holmes DR, O’Neill WW, Hamm CW, Van de Werf F, Armstrong PW, on behalf of APEX AMI Investigators: Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. JACC 3 (no. 3): 343-351, 2010
  93. Serruys PW, Onuma Y, Garg S, Vranckx P, De Bruyne B, Morice MC, Colombo A, Macay C, Richardt G, Fajadet J, Hamm C, Schuijer M, Rademaker T, Wittebols K, Stoll HP, on behalf of the ARTS II Investigators: 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-elutiing stent in the treatment of patients with multivessel de novo coronary artery lesions. JACC 55 (no. 11): 1093-1101, 2010
  94. ten Berg JM, van’t Hof AW, Dill T, Heestermans T, van Werkum JW, Mosterd A, van Houwelingen G, Koopmans PC, Stella PR, Boersma E, Hamm C, on behalf of the On-Time 2 Study Group: Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. JACC 55 (no 22): 2446-2455, 2010
  95. Troidl C, Nef H, Voss S, Schilp A, Kostin S, Troidl K, Szardien S, Rolf A, Schmitz-Rixen T, Schaper W, Hamm CW, Elsässer A, Möllmann H: Calcium-dependent signalling is essential during collateral growth in the pig hind limb-ischemia model. J Mol Cell Cardiol 49 (1): 142-151, 2010
  96. Erkapic D, Kim WK, Weber M, Möllmann H, Berkowitsch A, Zaltsberg S, Pajitnev DJ, Rixe J, Neumann T, Kuniss M, Sperzel J, Hamm CW, Pitschner HF: Electrocardiographic and further predictors for permanent pacemaker requirement after transcatheter aortic valve implantation. Europace 12 (8): 1061-1062, 2010
  97. Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK: Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics. Clin Res Cardiol 99: 375-383, 2010
  98. Toma M, Buller CE, Westerhout CM, Fu Y, O’Neill WW, Holmes Jr DR, Hamm CW, Granger CB, and Armstrong PW, for the APEX-AMI Investigators: Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. Eur H J 31: 1701-1707, 2010
  99. Timmer JR, ten Berg J, Heestermans AA, Dill T, van Werkum JW, Dambrink JHE, Suryapranata H, Ottervanger JP, Hamm C, van ‘t Hof AWJ, on behalf of the Ongoing Tirofiban In Myocardial Infarction Evaluation (On-Time) 2 study group: Pre-hospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of the On-Time 2 trial. EuroIntervention 6: 336-342, 2010
  100. Heestermans T, van’t Hof AWJ, ten Berg JM, van Werkum JW, Boersma E, Mosterd A, Stella PR, van Zoelen AB, Gosselink ATM, Kochman W, Dill T, Koopmans PC, van Houwelingen G, Zijlstra F, and Hamm C: The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy. Am Heart J: 160: 1079-1084, 2010
  101. Smit JJJ, van Werkum JW, ten Berg J, Slingerland R, Ottervanger JP, Heestermans T, Dill T, Hamm C, van’t Hof AWJ, on behalf of the Ongoing Tirofiban in Myocardial Evaluation (On-Time) trial investigators: Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy. Heart 96: 1815-1820, 2010
  102. Timmer JR, ten Berg J, Heestermans AA, Dill T, van Werkum JW, Dambrink JHE, Suryapranata H, Ottervanger JP, Hamm C, van’t Hof AWJ, on behalf of the Ongoing Tirofiban In Myocardial Infarction Evaluation (On-Time) 2 study group: Pre-hospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of the On-Time 2 trial. EuroIntervention 6 (3): 336-342, 2010
  103. Szardien S, Nef HM, Möllmann H, Voss S, Troidl C, Liebetrau C, Rolf A, Rixe J, Weber M, Hamm CW: Transient elevation of NT-pro-BNP as a predictor for myocardial ischemia. Clin Res Cardiol 99: 857-859, 2010
  104. Campo dell’Orto M, Hamm C, Rolf A, Dill T, Seeger FH, Walcher F, Breitkreutz R: Echokardiographie als Wegweiser in der Peri-Reanimation. Ein Advanced-Life-Support-konformes Konzept. Kardiologe 4: 407-424, 2010
  105. Topol EJ, Bousser MG, Fox KAA, Creager MA, Despers JP, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL, for The Crescendo Investigators: Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 376: 517-523, 2010
  106. Hermanides RS, Heestermans AACM, ten Berg JM, Gosselink ATM, Ottervanger JP, van Houwelingen G, Kolkman JJE, Stella PR, Dill T, Hamm C, van’t Hof AWJ: High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a subgroup analysis of the On-TIME 2 trial. Heart 97 (no 2): 106-111, 2011

© 2010-2024 Prof. Dr. C. Hamm